Zymeworks Presents Safety And Anti-Tumor Activity Data From The Ongoing Phase I Study Of ZW25 At ASCO Annual Meeting (ASCO 2017) Post author:Sam Post published:June 4, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Mirati Therapeutics Reports Second Quarter 2017 Financial Results August 3, 2017 Stanford University Clinical Geneticist Begins Presidency With The March 22, 2017 Johnson & Johnson Forges Peptide Discovery Pact Worth $1.5 Billion With Japanese Biopharma Peptidream April 6, 2017
Johnson & Johnson Forges Peptide Discovery Pact Worth $1.5 Billion With Japanese Biopharma Peptidream April 6, 2017